A Follow-up Evaluation Study of the Safety and Efficacy of PRI-724 Administration in Patients With Cirrhosis Due to Hepatitis C
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2018
Price : $35 *
At a glance
- Drugs PRI 724 (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
- 17 Jul 2018 Status changed from active, no longer recruiting to completed.
- 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.